SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Söderström Ann 1961)
 

Search: WFRF:(Söderström Ann 1961) > Treatment of chroni...

  • Lindh, Magnus,1960Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine (author)

Treatment of chronic hepatitis B infection : an update of Swedish recommendations

  • Article/chapterEnglish2008

Publisher, publication year, extent ...

  • 2009-07-08
  • London :Taylor & Francis,2008
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-4746
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-4746URI
  • https://doi.org/10.1080/00365540802154769DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-23386URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-89263URI
  • https://lup.lub.lu.se/record/1186306URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:117274919URI
  • https://gup.ub.gu.se/publication/87245URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:for swepub-publicationtype

Notes

  • The main goal for treatment of chronic hepatitis B is to prevent complications such as liver cirrhosis or hepatocellular carcinoma. Knowledge from population studies of the long-term risk of chronic HBV infection, as well as the recent introduction of pegylated interferon and additional nucleoside analogues has changed the therapeutic situation. Recently, a Swedish expert panel convened to update the national recommendations for treatment. The panel recommends treatment for patients with active HBV infection causing protracted liver inflammation or significant liver fibrosis, verified by liver histology. In general, pegylated interferon alpha-2a is recommended as first-line treatment, in particular for HBeAg-positive patients with HBV genotypes A or B. Among nucleoside analogues, entecavir is the first choice and adefovir or tenofovir can be used as alternatives. Lamivudine monotherapy is not recommended due to the high risk of resistance development. Combinations of nucleoside analogues such as tenofovir and lamivudine or emtricitabine are alternatives for patients with non-response or infection with resistant variants, or as first choice for patients with advanced liver disease. Nucleoside analogue treatment should be monitored to detect primary non-response and virological breakthrough. Special recommendations are given for HBV/HIV coinfected patients, immunosuppressed patients, children, and for treatment before and after liver transplantation. The present guideline is translated from Swedish, where it is published on the MPA and RAV websites (www.mpa.se and www.rav.nu.se) including 7 separate papers based on thorough literature search. The complete reference list can be received from the Medical Products Agency upon request.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Uhnoo, IngridSwedish Medical Products Agency, Uppsala, Sweden (author)
  • Bläckberg, JonasLund University,Lunds universitet,Infektionsmedicin,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Infection Medicine (BMC),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)infek-bg (author)
  • Duberg, Ann-SofiÖrebro universitet,Hälsoakademin(Swepub:oru)adg (author)
  • Friman, Styrbjörn,1948Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences(Swepub:gu)xfrist (author)
  • Fischler, BjörnKarolinska Institutet (author)
  • Karlström, Olof (author)
  • Norkrans, Gunnar,1944Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine(Swepub:gu)xnorgu (author)
  • Reichard, Olle (author)
  • Sangfeldt, PerUppsala universitet,Infektionssjukdomar (author)
  • Söderström, Ann,1961 (author)
  • Sönnerborg, AndersKarolinska Institutet (author)
  • Weiland, OlaKarolinska Institutet (author)
  • Wejstål, Rune,1952Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine(Swepub:gu)xwejru (author)
  • Wiström, Johan,1949-Umeå universitet,Infektionssjukdomar(Swepub:umu)jowi0029 (author)
  • Göteborgs universitetInstitutionen för biomedicin, avdelningen för infektionssjukdomar (creator_code:org_t)

Related titles

  • In:Scandinavian Journal of Infectious DiseasesLondon : Taylor & Francis40:6-7, s. 436-4500036-55481651-1980

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view